ALFA Finder| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 3.0 | 3.1 | 3.1 |
| Other income | 0.2 | 0.0 | 0.1 |
| Total income | 3.2 | 3.2 | 3.1 |
| Profit before exceptional items & tax | 0.2 | 0.3 | 0.2 |
| Profit before tax | 0.2 | 0.3 | 0.2 |
| Net profit | 0.2 | 0.2 | 0.1 |
| Operating margin | 6.2% | 9.4% | 6.5% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +100.00% |
|---|---|
| Net profit, quarter on quarter | +0.00% |
| Revenue, year on year | -3.20% |
| Operating profit, year on year | -100.00% |
| Operating profit, quarter on quarter | -100.00% |
BSE results filing, NSE: ISHITADR. Figures extracted from the filing.
Ishita Drugs & Industries Ltd: key numbers
- Share price
- ₹72.62
- Market cap
- ₹21.72 Cr
- Revenue (annual)
- ₹14.66 Cr
- Net profit (annual)
- ₹0.78 Cr
- P/E (TTM)
- 30.0×Sector 43.8×
- Promoter holding
- 50.04%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Ishita Drugs & Industries Ltd
All →Ishita Drugs & Industries Board Meeting Date
Ishita Drugs & Industries will hold a board meeting on 03/11/2026 to approve Q1 FY2027 unaudited results. The filing is a prior intimation under Regulation 29 of SEBI LODR.
Ishita Drugs & Industries Other Announcement
Ishita Drugs & Industries Ltd submitted its quarterly shareholding pattern under Regulation 31, disclosing the promoter and public shareholdings as of September 30, 2026.
Ishita Drugs & Industries Management Change
Ishita Drugs and Industries Limited has re-appointed Mrs. Abha Agrawal as a Non-Executive Non-Independent Director. The company also re-appointed M/s. Jaymin Shah & Associates as Statutory Auditors.
Ishita Drugs & Industries Other Announcement
Ishita Drugs & Industries Ltd has re-appointed M/s. Jaymin Shah & Associates as its Statutory Auditor from the 33rd to the 34th AGM.
Ishita Drugs & Industries Annual General Meeting
Ishita Drugs & Industries Ltd. held its 33rd Annual General Meeting on September 30, 2026. The meeting covered financial statements, auditor appointments, and director re-appointment.
Ishita Drugs & Industries Debt & Borrowing: ₹11.75 Cr
Ishita Drugs approved Rs.11.75 Crore borrowings from HDFC Bank, covering a term loan and working capital facility. This is within shareholder-approved borrowing limits from its 31st AGM.
- Value
- ₹11.75 Cr